Pharmacokinetic-pharmacodynamic modeling of methylxanthine derivatives in mice challenged with high-dose lipopolysaccharide

Pharmacology

Volumn 85, Issue 5, 2010, Pages 264-271

  Wyska, Elzbieta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Lisofylline; Pentoxifylline; Pharmacokinetic pharmacodynamic modeling; TNF

Indexed keywords

LIPOPOLYSACCHARIDE; LISOFYLLINE; METHYLXANTHINE DERIVATIVE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG POTENCY; EXPERIMENTAL MOUSE; IC 50; IN VIVO STUDY; INFLAMMATION; MALE; MAXIMUM PLASMA CONCENTRATION; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; HALF LIFE TIME; TOXICITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MODELS, BIOLOGICAL; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR-ALPHA; XANTHINES;

EID: 77950601004     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000288734     Document Type: Article

References (35)

1. Yang Z, Chen M, Nadler JL: Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol 2005; 69: 1-5.
2. Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S: Prospective, randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin-2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997; 3: 565-572.
3. List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW, Lisofylline Marrow Transplant Study Group: A randomized placebocontrolled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2000; 25: 283-291.
4. Rice GC, Brown PA, Nelson RJ, Bianco JA, Singer JW, Bursten S: Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci USA 1994; 91: 3857-3861.
5. Abdel-Salam OME, Baiuomy AR, El- Shenawy SM, Arbid MS: The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res 2003; 47: 331-340.
6. Bursten SL, Federighi D, Wald J, Meengs B, Spickler W, Nudelman E: Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. J Pharmacol Exp Ther 1998; 284: 337-345.
7. Colburn WA, Lee JW: Biomarkers, validation and pharmacokinetic- pharmacodynamic modelling. Clin Pharmacokinet 2003; 42: 997-1022.
8. Waage A, Espevik T, Lamvik J: Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 1986; 24: 739-743.
9. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-357.
10. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL: Patterns of cytokine evolution (tumor necrosis factor- and interleukin- 6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997; 25: 1813-1819.
11. Van Furth AM, Verhard-Seijmonsbergen EM, van Furth R, Langermans JA: Effect of lisofylline and pentoxifylline on the bacterial- stimulated production of TNF- , IL-1 and IL-10 by human leucocytes. Immunology 1997; 91: 193-196.
12. Lin HI, Chu SJ, Wang D, Feng NH: Pharmacological modulation of TNF- production in macrophages. J Microbiol Immunol Infect 2004; 37: 8-15.
13. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grünwald C, Knobler R, Schwarz A, Luger TA, Schwarz T: Pentoxifylline in vivo down-regulates the release of IL-1 , IL-6, IL-8 and tumour necrosis factor- by human peripheral blood mononuclear cells. Immunology 1994; 83: 262-267.
14. Schandene L, Vandenbussche P, Crusiaux A, Alegre ML, Abramowicz D, Dupont E, Content J, Goldman M: Differential effect of pentoxifylline on the production of tumour necrosis factor- (TNF- ) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992; 76: 30-34.
15. Zeni F, Pain P, Vindimian M, Gay JP, Gery P, Bertrand M, Page Y, Page D, Vermesch R, Bertrand JC: Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996; 24: 207-214.
16. Lauterbach R, Pawlik D, Kowalczyk D, Ksyciški W, Helwich E, Zembala M: Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants. Crit Care Med 1999; 27: 807-814.
17. Shukla R, Vender RB: Pharmacology of TNF inhibitors; in Weinberg JM, Buchholz R (eds): TNF- Inhibitors. Basel, Birkhäuser Verlag, 2006, pp 23-44.
18. Wyska E, Pȩkala E, Szymura-Oleksiak J: Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. Chirality 2006; 18: 644-651.
19. Chakraborty A, Yeung S, Pyszczynski NA, Jusko WJ: Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. J Pharm Sci 2005; 94: 590-603.
20. Gozzi P, Pǻhlman I, Palmér L, Grönberg A, Persson S: Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor- levels in the mouse. J Pharmacol Exp Ther 1999; 291: 199-203.
21. Foster SJ, McCormick LM: Tumour necrosis factor production by rat blood and its ex vivo pharmacological modulation. Agents Actions 1993; 39:C61-C63.
22. Chakraborty A, Blum RA, Cutler DL, Jusko WJ: Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. Clin Pharmacol Ther 1999; 65: 304-318. (Pubitemid 29142937)
23. Gordon K, Wollenberg L, DeForge E, Bolgos G, Remick DG: Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am J Pathol 1993; 143: 1121-1130.
24. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D: Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005; 12: 60-67.
25. Buras JA, Holzmann B, Sitkovsky M: Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005; 4: 854-865.
26. Shin HS, Slattery JT: CYP3A4-mediated oxidation of lisofylline to lisofylline 4,5-diol in human liver microsomes. J Pharm Sci 1998; 87: 390-393.
27. Lee SH, Slattery JT: Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Disp 1997; 25: 1354-1358.
28. Nicklasson M, Björkman S, Roth B, Jönsson M, Hoglund P: Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 2002; 14: 643-652.
29. Wyska E, Szymura-Oleksiak J, Pȩkala E, Obruśnik A: Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice. J Pharm Pharmacol 2007; 59: 495-501.
30. Wyska E: Pretreatment with R(+)-verapamil significantly reduces mortality and cytokine expression in murine model of septic shock. Int Immunopharmacol 2009; 9: 478-490.
31. Semmler J, Gebert U, Eisenhut T, Moeller J, Schönharting MM, Alléra A, Endres S: Xanthine derivatives: comparison between suppression of tumour necrosis factor- production and inhibition of cAMP phosphodiesterase activity. Immunology 1993; 78: 520-525.
32. Badger AM, Olivera DL, Esser KM: Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circ Shock 1994; 44: 188-195.
33. Ette E, Kelman AW, Howie CA, Whiting B: Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm 1994; 23: 551-566.
34. Dedrick RL: Animal scale-up. J Pharmacokinet Biopharm 1973; 1: 435-461.
35. Mager DE, Woo S, Jusko WJ: Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 2009; 24: 16-24.